Table 4.
Association of CC16 mRNA Expression Levels in Bronchial Epithelial Cells with Asthma Exacerbations in Asthmatics
| SARP Cross-sectional Cohort Microarray mRNA (Asthmatics, n = 128) | Exacerbation (Yes/No) in the Last 12 mo (n = 124) |
Number of exacerbations in the prospective 3 yr (n = 0) RR (P Value)† |
||
|---|---|---|---|---|
| No (n = 77) | Yes (n = 47) | OR (P Value)* | ||
| CC16 mRNA expression levels (log2) | 18.2 ± 0.83 | 17.5 ± 1.46 | 0.62 (0.012) | NA |
| SARP Longitudinal Cohort RNAseq (Asthmatics, n = 114) | Exacerbation (Yes/No) in the Last 12 mo (n = 114) |
Number of exacerbations in the prospective 3 yr (n = 92) RR (P Value)† |
||
|---|---|---|---|---|
| No (n = 63) | Yes (n = 51) | OR (P Value)* | ||
| CC16 mRNA expression levels (ln) | 15.6 ± 0.93 | 15.0 ± 1.02 | 0.55 (0.0067) | 0.57 (0.015) |
Definition of abbreviations: ln = natural logarithm; log2 = logarithm base 2; OR = odds ratio; RNAseq = RNA sequencing; RR = risk ratio; SARP = Severe Asthma Research Program.
*
OR and P value were generated using a logistic regression model adjusted for age, sex, body mass index, race, and batch effect.
†
RR and P value were generated using a negative binomial model adjusted for age, sex, body mass index, race, and batch effect. CC16 mRNA expression levels were logarithm base 2- and natural logarithm-transformed in the SARP cross-sectional cohort and longitudinal cohort, respectively.